The Vanguard Group 13D and 13G filings for CytomX Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-13 5:02 pm Purchase |
2023-12-29 | 13G | CytomX Therapeutics, Inc. CTMX |
The Vanguard Group | 4,902,943 7.320% |
317,222 (+6.92%) |
Filing |
| 2023-02-09 11:16 am Sale |
2022-12-30 | 13G | CytomX Therapeutics, Inc. CTMX |
The Vanguard Group | 4,585,721 6.940% |
-522,270 (-10.22%) |
Filing |
| 2022-02-09 3:43 pm Purchase |
2021-12-31 | 13G | CytomX Therapeutics, Inc. CTMX |
The Vanguard Group | 5,107,991 7.830% |
2,173,567 (+74.07%) |
Filing |
| 2021-02-10 10:46 am Purchase |
2020-12-31 | 13G | CytomX Therapeutics, Inc. CTMX |
The Vanguard Group | 2,934,424 6.350% |
244,820 (+9.10%) |
Filing |